Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

Medigene AG. (5/18/15). "Press Release: Medigene to Participate in Investment and Scientific Conferences". Martinsried.

Region Region Wien (Vienna)
  Country Austria
Organisations Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
  Organisation 2 Ludwig Institute for Cancer Research (LICR)
Products Product DC vaccine (dentritic cell vaccine)
  Product 2 BioEquity Europe 2015 Vienna
Index term Index term Medigene–Informa: investor conference, 201505 supply service Medigene participant at BioEquity Europe 2015 in Vienna
Persons Person Llewellyn-Davies, Peter (Apeiron 201807– CEO before CFO+CBO before Accellerate Partners + Medigene + Wilex)
  Person 2 Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München)

Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in three upcoming investment and scientific conferences:

BioEquity Europe - The 16th Collaborative Gathering of Corporate & Investment Communities for the European Life Science

Date: 19 - 20 May 2015
Location: Vienna, Austria
Company presentation: 19 May 4.40 pm local time
Speaker: Peter Llewellyn-Davies, CFO Medigene AG

Conférence du LICR, Ludwig Center for Cancer Research of the University of Lausanne

Date: 21 May 2015
Location: Lausanne, Switzerland
Speaker: Dolores J. Schendel, CSO Medigene AG

ASCO, American Society of Clinical Oncology Annual Meeting 2015

Date: 29 May - 02 June 2015
Location: Chicago, USA

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact Medigene

Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01

Record changed: 2017-07-02


Picture [LSUS] – The Business Web Portal 650x112px

More documents for Medigene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 650x65px

» top